AI Technology Group Inc. announced it has signed a definitive agreement dated July 31, 2025, to acquire AVM Biotechnology Inc., a company developing AVM0703, an investigational small-molecule cancer immunotherapy designed to reactivate the body's reserve immune system. The acquisition positions AI Technology Group to advance a novel cancer treatment that has shown promising safety data across 90 patients treated to date.
Novel Immunotherapy Mechanism
AVM0703 represents a unique approach to cancer treatment, designed to reactivate the body's Reserve Immune System through a simple one-hour outpatient infusion. The drug targets bispecific gamma/delta TCR+ and invariant TCR+ T lymphocytes and Natural Killer T cells, which recognize and kill cancer and other abnormal cells in the body. Additionally, AVM0703 stimulates hematopoietic stem cell and mesenchymal stem cell production.
The treatment offers significant practical advantages over existing cancer therapies. AVM0703 is room-temperature stable with a 2-year shelf life, can be administered without requiring a comprehensive cancer center, and does not require cell engineering, radiation, or complex manufacturing processes.
Clinical Development Progress
AVM0703 currently holds U.S. FDA investigational new drug application (IND) status and is in Phase 2 human trials for relapsed/refractory non-Hodgkin lymphoma (NHL) patients. The drug is also being evaluated through individual patient INDs for other blood cancers and various solid tumors.
The clinical program has demonstrated notable safety results across multiple patient populations. Ninety patients have been treated across Phase 1b/2 clinical trials, FDA Expanded Access, and global Compassionate Use programs, receiving over 250 total infusions. No safety signals have been observed in any of the 90 subjects treated to date, even with repeat dosing extending up to 19 cycles.
In FDA Expanded Access and global Compassionate Use programs specifically, 60 patients with 20 different types of solid tumors or blood cancers, or with graft-versus-host disease (GvHD), non-healing wounds, or autoimmune diseases have been treated with repeat dosing of up to 19 infusions per patient with no cumulative toxicity observed.
Broader Therapeutic Applications
Beyond oncology, preclinical and clinical research suggests AVM0703 has broad applications to autoimmune diseases such as rheumatoid arthritis and diabetes, as well as infectious diseases. This versatility stems from the drug's mechanism of action in reactivating the body's natural immune surveillance systems.
Leadership and Intellectual Property
AVM Biotechnology is led by Dr. Theresa Deisher, a stem-cell and immunology expert with over 30 years of drug development experience at companies including Genentech, Amgen, and Immunex. Dr. Deisher holds a PhD in Molecular and Cellular Physiology from Stanford University and is an inventor on more than 47 patents. AVM maintains a global patent portfolio with coverage extending into the 2040s.
Financial Structure and Future Plans
The acquisition is being supported by a private financing of at least $14 million at $2.50 per share to support AVM's clinical development and working capital requirements. Under the agreement, a newly formed subsidiary of AI Technology Group will merge with AVM, making AVM a wholly owned subsidiary at closing, subject to customary closing conditions.
Following the closing, AI Technology Group anticipates changing its corporate name and ticker symbol to align with the combined business, subject to regulatory approval. The company has filed an amended Form 10 with the Securities and Exchange Commission and will become subject to ongoing SEC reporting requirements upon effectiveness.
